On November 29, 2016 Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis technology platform, reported that the company will be presenting at the EORTC-AACR-NCI Symposium being held November 29-December 1 at the Internationales Congress Center München in Munich, Germany (Press release, Argos Therapeutics, NOV 29, 2016, View Source [SID1234516822]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Irina Tcherepanova, Ph.D., senior director of research and development for Argos, will give a poster presentation entitled "Development of an RNA loaded Dendritic Cell (DC) immunotherapy starting from tissue obtained via needle biopsy". The poster will be exhibited in the meeting exhibition hall throughout the day on November 30th.
The EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium is hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association of Cancer Research (AACR) (Free AACR Whitepaper), and brings together academics, scientists, and industry representatives from around the world to review the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.
For more information visit View Source
About the Arcelis Technology Platform
Arcelis is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis process uses only a small disease sample or biopsy as the source of disease-specific antigens and the patient’s own dendritic cells, which are optimized from cells collected by a leukapheresis procedure. The proprietary process uses RNA isolated from the patient’s disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient’s plasma and administered via intradermal injection as an individualized immunotherapy.